These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16286629)

  • 1. Periocular cutaneous pigmentary changes associated with bimatoprost use.
    Galloway GD; Eke T; Broadway DC
    Arch Ophthalmol; 2005 Nov; 123(11):1609-10. PubMed ID: 16286629
    [No Abstract]   [Full Text] [Related]  

  • 2. Two new ophthalmic solutions enter glaucoma market.
    Am J Health Syst Pharm; 2001 Jun; 58(12):1080, 1086. PubMed ID: 11449848
    [No Abstract]   [Full Text] [Related]  

  • 3. Bimatoprost-induced periocular skin hyperpigmentation: histopathological study.
    Kapur R; Osmanovic S; Toyran S; Edward DP
    Arch Ophthalmol; 2005 Nov; 123(11):1541-6. PubMed ID: 16286616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
    Sodhi PK; Verma L; Ratan SK
    Am J Ophthalmol; 2004 Apr; 137(4):783. PubMed ID: 15059736
    [No Abstract]   [Full Text] [Related]  

  • 5. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
    Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
    Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
    Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
    Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand.
    Wanichwecha-Rungruang B; Iemsomboon W
    J Med Assoc Thai; 2005 Sep; 88(9):1228-35. PubMed ID: 16536109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deepening of lid sulcus from topical bimatoprost therapy.
    Peplinski LS; Albiani Smith K
    Optom Vis Sci; 2004 Aug; 81(8):574-7. PubMed ID: 15300114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
    Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
    Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy.
    Yam JC; Yuen NS; Chan CW
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):471-2. PubMed ID: 19857110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost.
    Herndon LW; Asrani SG; Williams GH; Challa P; Lee PP
    Arch Ophthalmol; 2002 Jun; 120(6):847-9. PubMed ID: 12049597
    [No Abstract]   [Full Text] [Related]  

  • 13. Modern alchemy: fixed combinations of glaucoma drugs.
    Katz LJ
    Am J Ophthalmol; 2005 Jul; 140(1):125-6. PubMed ID: 16038653
    [No Abstract]   [Full Text] [Related]  

  • 14. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension.
    Cohen JS; Gross RL; Cheetham JK; VanDenburgh AM; Bernstein P; Whitcup SM
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S45-52. PubMed ID: 15016561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
    Gandolfi SA; Cimino L
    Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F; Ermis SS; Inan UU
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
    Herndon LW; Robert D Williams ; Wand M; Asrani S
    Am J Ophthalmol; 2003 May; 135(5):713-5. PubMed ID: 12719085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost.
    Herane MI; Urbina F
    J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):644-5. PubMed ID: 15324422
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.